Dobsch, Philipp and Michels, Bernhard and Mueller-Schilling, Martina and Kandulski, Arne (2019) Therapeutic regimens using monoclonal antibodies in gastroenterology. INTERNIST, 60 (10). pp. 1043-1058. ISSN 0020-9554, 1432-1289
Full text not available from this repository. (Request a copy)Abstract
Therapeutic regimens using monoclonal antibodies have been implemented in clinical daily practice for various gastroenterological diseases, for therapeutic strategies in gastrointestinal (GI) oncology, and infectious diseases of the gastrointestinal tract. The main indications remain the therapy of chronic inflammatory bowel disease and in GI oncology. A new field has opened for targeted therapy with monoclonal antibodies of recurrent Clostridium difficile infection. In the nomenclature of monoclonal antibodies, the endings of the substances indicate the production or degree of "humanization" of the respective antibodies ("umab": fully human, recombinant antibody; "ximab": chimeric antibody with variable murine domain). For chronic inflammatory bowel disease, monoclonal antibodies has been developed to interfere with molecular targets of the inflammatory cascade in the underlying pathogenesis (tumor necrosis factor-alpha, interleukin-12 and -23; alpha 4 beta 7-integrins). The development of targeted therapies in the treatment of GI malignancies, monoclonal antibodies has been developed to interfere with substantial pathways of proliferation and apoptosis as well as neoplastic vascularization and neovascularization (e.g., vascular endothelial growth factor [VEGF] and VEGF receptor antibodies, epidermal growth factor receptor antibodies, HER2/neu antibodies). In the current review, we provide a summary of the current applications of monoclonal antibodies in the therapeutic treatment of gastroenterological diseases.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | METASTATIC COLORECTAL-CANCER; EVIDENCE-BASED CONSENSUS; NECROSIS-FACTOR-ALPHA; INFLAMMATORY-BOWEL-DISEASE; ANTI-TNF THERAPY; PHASE-III TRIAL; CROHNS-DISEASE; MAINTENANCE THERAPY; DOUBLE-BLIND; CLINICAL-RESPONSE; Molecular targeted therapy; Colorectal neoplasms; Stomach neoplasms; Crohn disease; Colitis; ulcerative |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin I |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 26 Mar 2020 13:47 |
| Last Modified: | 26 Mar 2020 13:47 |
| URI: | https://pred.uni-regensburg.de/id/eprint/26162 |
Actions (login required)
 |
View Item |
